Given that diarrhea from Capivasertib has a rapid onset within 12 days, clinicians should consider prophylactic loperamide. This proactive approach, especially for patients with pre-existing bowel issues, can help them tolerate the therapy from the start, rather than waiting for symptoms to appear.
Due to limited and delayed availability of endocrinologists, oncologists must be comfortable with the frontline management of metabolic side effects like hyperglycemia. This involves aggressive monitoring from the start and initiating treatment themselves, a necessary skill for effectively using drugs like Capivasertib, especially in practices outside the U.S.
The side effects of Capivasertib do not occur simultaneously. Rash and diarrhea typically present early, while hyperglycemia manifests later, within the first two months. This staggered onset provides a crucial window for clinicians to manage the initial toxicities before needing to address metabolic effects, simplifying patient care.
For prostate cancer patients with comorbidities like obesity and poorly controlled diabetes, initiating a GLP-1 agonist is beneficial regardless of cancer therapy. This intervention not only manages their metabolic syndrome but also makes it feasible and safer to administer potent drugs like Capivasertib, which can worsen hyperglycemia.
An expert expressed disappointment with Lutetium's efficacy in the metastatic hormone-sensitive setting, suggesting its benefit is lower than expected. A potential flaw in trial design was starting hormonal agents first, which can lower PSMA expression, thereby potentially reducing the radioligand's target and diminishing its therapeutic effect.